Platform Construction of Guangdong Provincial Key Laboratory of TCM Active Components and Gut Microbiomics (2024 Fiscal Year)

This project investigates chronic and severe diseases—including malignancies, diabetes mellitus, and inflammatory bowel disease—by characterizing gut microbial compositional/functional perturbations and their pathophysiological correlations with disease progression. Leveraging multi-omics platforms (high-throughput sequencing, metabolomics, and proteomics), we systematically identify and validate microbiota-regulating bioactive compounds derived from TCM. Mechanistic studies further delineate the molecular pathways and effector targets through which TCM-remodeled gut microbiota exerts disease-modulating effects, thereby bridging traditional pharmacology with contemporary systems biology paradigms.